Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads

The objective of this study was to assess the effect of food and timing of meals on the bioavailability of didanosine from encapsulated enteric-coated beads. Four different independent, open-label, single-dose, randomized, crossover studies were conducted in healthy subjects (n = 20-30). Didanosine (400 mg) was given concomitantly with a high-fat meal, light meal, yogurt, and applesauce. In addition, didanosine was given 1, 1.5, 2, and 3 hours before and 2 hours after a light meal. Statistical comparison with fasting conditions was made using the equivalence approach for Cmax (70%-143%) and AUC (80%-125%). The high-fat meal, light meal, yogurt, and applesauce decreased the Cmax by 46%, 22%, 30%, and 24%, respectively, and lowered the AUC by 19%, 27%, 20%, and 18%, respectively; statistical analyses indicated an indeterminate food effect, except for the Cmax for the high-fat meal. For 1 hour before meal, Cmax and AUC were lower by 15% and 24% and, for 2 hours after meal, were lower by 15% and 10%, respectively. There was an indeterminate food effect for 1 hour before the meal treatment; in addition, 2 hours after the meal, treatment approached statistical equivalence, missing narrowly on the lower bounds. For 1.5, 2, and 3 hours before meal treatments, Cmax values were unchanged, but AUC was lower by 10%, 4%, and 0%, respectively; lack of food effect was observed for all three treatments. Across studies, median time to Cmix ranged from 1.67 to 2.67 hours but was delayed by 2.5 to 3 hours with high-fat and light meals compared to fasting conditions. The half-life of didanosine was 1.5 to 2 hours. It was concluded that the bioavailability of didanosine from encapsulated enteric-coated beads was reduced by approximately 20% to 25% with food, which can be circumvented by taking didanosine on an empty stomach. The clinical significance of such moderate reductions in didanosine exposure with food, especially as part of a highly active antiretroviral therapy, is not clear.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Crespo, E. Ribera, I. Suarez-Lozano, P. Domingo, E. Pedrol, J. Lopez-Aldeguer, A. Munoz, C. Vilades, T. Sanchez, P. Viciana, et al. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort J. Antimicrob. Chemother., January 1, 2009; 63(1): 189 - 196. [Abstract] [Full Text] [PDF]

				X.-J. Zhou, D. M. Lloyd, G. C. Chao, and N. A. Brown Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J. Clin. Pharmacol., March 1, 2006; 46(3): 275 - 281. [Abstract] [Full Text] [PDF]

				B. P. Kearney, J. R. Sayre, J. F. Flaherty, S.-S. Chen, S. Kaul, and A. K. Cheng Drug-Drug and Drug-Food Interactions Between Tenofovir Disoproxil Fumarate and Didanosine J. Clin. Pharmacol., December 1, 2005; 45(12): 1360 - 1367. [Abstract] [Full Text] [PDF]

				C. la Porte, C. Verweij-van Wissen, N. van Ewijk, R. Aarnoutse, P. Koopmans, P. Reiss, M. Stek Jr, Y. Hekster, and D. Burger Pharmacokinetic Interaction Study of Indinavir/Ritonavir and the Enteric-Coated Capsule Formulation of Didanosine in Healthy Volunteers J. Clin. Pharmacol., February 1, 2005; 45(2): 211 - 218. [Abstract] [Full Text] [PDF]